UCL70802 / UTC Therap - LARVOL DELTA

First-in-Human Phase I Study of UCL70802, a LACO-Stim armored Anti-CD70 CAR-T Cell Therapy, in patients with Metastatic clear cell renal cell carcinoma (mccRCC) (ESMO 2026) - No abstract available

CAR T-Cell Therapy • Clinical • First-in-human • Metastases • P1 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • CD70

First-in-human phase I study of UCL70802, a LACO-Stim armored Anti-CD70 CART cell therapy, in patients with metastatic clear cell renal cell carcinoma (mccRCC) (AACR 2026) - "UCL70802 demonstrated a manageable safety profile and promising preliminary antitumor activity in mccRCC patients. Its dual mechanism -combining direct CAR-mediated targeting with systemic immune activation via LACO-Stim-may help overcome resistance seen with conventional CAR-T therapies. Dose escalation continues to further assess efficacy and safety."

CAR T-Cell Therapy • Clinical • First-in-human • Metastases • P1 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • CD40 • CD70

CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital

New P1/2 trial • Gastrointestinal Cancer • Oncology • Solid Tumor • CD70 • IL10 • IL2 • IL6 • TNFA

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital

New P1/2 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD70 • IL10 • IL2 • IL6 • TNFA